Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06146725 · ClinicalTrials.gov registry record
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
A clinical trial of Glioblastoma and Glioblastoma Multiforme, sponsored by Jasper Gerritsen.
- Recruiting
- Registry status
- 564
- Enrollment target
- 8
- Study locations
NCT06146725 is a study of Glioblastoma and Glioblastoma Multiforme that is actively recruiting participants, run by Jasper Gerritsen. The registered enrollment target is 564 participants, above the 106-participant average among 199 other Glioblastoma trials with a reported enrollment target (432% higher). The trial reports 8 study locations across 5 states.
The verdict
NCT06146725, a study of Glioblastoma and Glioblastoma Multiforme, is actively recruiting participants, sponsored by Jasper Gerritsen.
- RECRUITING
- Registry status
- 564 participants
- Enrollment target
- 8
- Study locations
Study Summary
There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internationally and at times even within an instiutition. This study aims to compare the effects of maximal tumor resection versus tissue biopsy on survival, functional, neurological, and quality of life outcomes in these patient subgroups. Furthermore, it evaluates which modality would maximize the potential to undergo adjuvant treatment. This study is an international, multicenter, prospective, 2-arm cohort study of observational nature. Consecutive HGG patients will be treated with resection or biopsy at a 3:1 ratio. Primary endpoints are: 1) overall survival (OS) and 2) proportion of patients that have received adjuvant treatment with chemotherapy and radiotherapy. Secondary endpoints are 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months and 6 months after surgery 2) progression-free survival (PFS); 3) quality of life at 6 weeks, 3 months and 6 months after surgery and 4) frequency and severity of Serious Adverse Events (SAEs). Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.
Conditions Studied
Interventions
- PROCEDURE Tumor biopsy
- PROCEDURE Tumor resection
Study Locations (8)
Other
- University Hospital Leuven - Leuven
- University Hospital Heidelberg - Heidelberg
- Haaglanden Medical Center - The Hague
- Inselspital Universitätsspital Bern - Bern
California
- University of California, San Francisco - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
Bavaria
- Technical University Munich - Munich
South Holland
- Erasmus Medical Center - Rotterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2029-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06146725
The ClinicalTrials.gov registry entry for NCT06146725 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 564 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 106-participant average among 199 other Glioblastoma trials with a reported enrollment target (432% higher). The listed sponsor is Jasper Gerritsen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Tumor biopsy is the first listed.
NCT06146725 reports 8 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06146725 about?
NCT06146725 is a clinical study titled "The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)". There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internationa...
What is the current status of trial NCT06146725?
This trial is currently recruiting. The enrollment target is 564 participants. The study started on 2023-01-01. Estimated completion is 2029-01-01.
What conditions does trial NCT06146725 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult.
What interventions are being tested in trial NCT06146725?
The interventions under investigation include: Tumor biopsy (PROCEDURE), Tumor resection (PROCEDURE).
Who is sponsoring clinical trial NCT06146725?
This trial is sponsored by Jasper Gerritsen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06146725 being conducted?
This trial has 8 study locations across California, Massachusetts, Bavaria, South Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
RECRUITING
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.